ArticleBMC infectious diseases2017
Antimicrobial susceptibility testing of rapidly growing mycobacteria isolated in Japan.
Article in BMC infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.
- Global trends in the proportion of macrolide-resistant Mycobacterium Species: A systematic review and meta-analysis.PloS one · 2025Pooled it
- Negligible clinical impact of subsequent non-tuberculous mycobacteria isolation during MDR/RR-TB treatment: a 9-year retrospective cohort study from Wenzhou, China.BMC infectious diseases · 2025Article
- Molecular Characterization and Antibiograms of Nontuberculous Mycobacterium Infections in Kashgar, China.Current microbiology · 2025Article
- Drug susceptibility profiles ofJournal of medical microbiology · 2025Article
- Cutaneous Nontuberculous Mycobacteria Infections Following Cosmetic Procedures: A Retrospective Study.Infection and drug resistance · 2025Article
- Managing Complicated Nontuberculous Mycobacteria Infections in Plastic Surgery.Plastic and reconstructive surgery. Global open · 2024Article
- Effectiveness and safety of regimens containing linezolid for treatment of Mycobacterium abscessus pulmonary Disease.Annals of clinical microbiology and antimicrobials · 2023Article
- Article
- Screening and Drug Resistance Analysis of Non-Tuberculous Mycobacteria in Patients with Suspected Pulmonary Tuberculosis on the Hainan Island, China.Infection and drug resistance · 2023Article
- Natural Products Lysobactin and Sorangicin A ShowMicrobiology spectrum · 2022Article
- A systematic scoping review of faropenem and other oral penems: treatment of Enterobacterales infections, development of resistance and cross-resistance to carbapenems.JAC-antimicrobial resistance · 2022Article
- Epidemiology, Outcomes and Tolerability of Protracted Treatment of Nontuberculous Mycobacterial Infections at a Community Teaching Hospital in the Southeastern United States.Antibiotics (Basel, Switzerland) · 2022Article
- Dual Infection of an Open Fracture Caused byAntibiotics (Basel, Switzerland) · 2022Article
- High Rates of Antimicrobial Resistance in Rapidly Growing Mycobacterial Infections in Taiwan.Pathogens (Basel, Switzerland) · 2022Article
- Antibiotic Susceptibility of Mycobacteria Isolated from Ornamental Fish.Journal of veterinary research · 2022Article
- Factors Associated with Treatment Outcome in Patients with Nontuberculous Mycobacterial Pulmonary Disease: A Large Population-Based Retrospective Cohort Study in Shanghai.Tropical medicine and infectious disease · 2022Article
- A genomic data resource for predicting antimicrobial resistance from laboratory-derived antimicrobial susceptibility phenotypes.Briefings in bioinformatics · 2021Article
- A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus ActivityAntimicrobial agents and chemotherapy · 2021Article
- Nationwide surveillance of antimicrobial susceptibility of 509 rapidly growing mycobacteria strains isolated from clinical specimens in Japan.Scientific reports · 2021Article
- Repurposing Avermectins and Milbemycins againstAntibiotics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDifficult-to-treat infections caused by rapidly growing mycobacteria (RGM) are increasingly observed in clinical settings. However, studies on antimicrobial susceptibilities and effective treatments against RGM in Japan are limited.
methodsWe conducted susceptibility testing of potential antimicrobial agents, including tigecycline and tebipenem, against RGM. Clinical RGM isolates were collected from a university hospital in Japan between December 2010 and August 2013. They were identified using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and the sequencing of 16S rRNA, rpoB, and hsp65 genes. The samples were utilized for susceptibility testing using 16 antimicrobials, with frozen broth microdilution panels.
resultsForty-two isolates were obtained: 13, Mycobacterium abscessus complex; 12, Mycobacterium chelonae; 9, Mycobacterium fortuitum; and 8, M. fortuitum group species other than M. fortuitum. Different antimicrobial susceptibility patterns were observed between RGM species. Clarithromycin-susceptible strain rates were determined to be 0, 62, and 100% for M. fortuitum, M. abscessus complex, and M. chelonae, respectively. M. abscessus complex (100%) and >80% M. chelonae isolates were non-susceptible, while 100% M. fortuitum group isolates were susceptible to moxifloxacin. Linezolid showed good activity against 77% M. abscessus complex, 89% M. fortuitum, and 100% M. chelonae isolates. Regardless of species, all tested isolates were inhibited by tigecycline at very low minimal inhibitory concentrations (MICs) of ≤0.5 μg/mL. MICs of tebipenem, an oral carbapenem, were ≤4 μg/mL against all M. fortuitum group isolates.
conclusionsOur study demonstrates the importance of correct identification and antimicrobial susceptibility testing, including the testing of potential new agents, in the management of RGM infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.